Minnesota-based medical device major
) latest cardiac resynchronization therapy-pacemaker (CRT-P) - Viva
CRT-P - has duly received the U.S. Food and Drug Administration
(FDA) approval. This device is used for the treatment of patients
who suffer from heart failure or atrioventricular (AV) block.
Heart failure patients, who have developed arrhythmia-irregular
heart rhythms, are treated with cardiac resynchronization therapy
or biventricular pacing. In such patients, CRT-P improves the
efficiency of heart and increases blood flow.
Patients with mildly symptomatic, moderate or severe heart
failure have been successfully treated with Medtronic's CRT devices
for a long time. In recent times, they have also been used in
patients with AV block and reduced ejection fraction - a measure of
The Viva CRT-P incorporates Medtronic's exclusive AdaptiveCRT
software. AdaptiveCRT is a unique algorithm that has helped
considerably improve CRT patients' response to the therapy. It also
has the capability to minimize atrial fibrillation (AF) in
heart-failure patients, compared to standard biventricular
Drawing benefits from the AdaptivCRT algorithm, Viva CRT-P can
provide personalized therapy to each individual patient by
maintaining normal heart rhythms and mechanically adapting to the
patient's requirement on a minute-by-minute basis. Per recently
released statistics, the AdaptivCRT software has minimized 30-day
hospital readmissions for heart failure by 47% and has also brought
down AF-related healthcare utilizations (hospitalizations,
emergency department or clinic visits) by 55%.
It is believed that patients implanted with Viva CRT-P will
likely benefit through improved response rates to cardiac
resynchronization therapy. This will allow them to make a healthy
return to their normal lives and avoid further instances of
Advanced diagnostics tools, such as OptiVol Fluid Status
Monitoring and Cardiac Compass Report also comprise a part of Viva
CRT-P. These instruments offer insight into patients' physiological
conditions. These tools can determine patients who are at the risk
of rehospitalization within 30 days of discharge - a factor deemed
as a critical quality measure.
At present, Medtronic is focused at improving cardiac
resynchronization therapy through research and upgraded therapies.
Management believes the launch of Viva CRT-P marks yet another
milestone within Medtronic's line of pioneer CRT-devices.
Currently, Medtronic carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical products industry include ICU
Medical, Inc. (
), Abaxis, Inc. (
) and Chimerix, Inc. (
). While ICU Medical sports a Zacks Rank #1 (Strong Buy), both
Abaxis and Chimerix hold a Zacks Rank #2 (Buy) each.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
CHIMERIX INC (CMRX): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis
To read this article on Zacks.com click here.